{
  "retracted": false,
  "timestamp": 1158019200000,
  "updates": [
    {
      "timestamp": 1495865369544,
      "identifier": {
        "doi": "10.1212/01.wnl.0000244478.20128.b8"
      },
      "type": "correction"
    }
  ],
  "identifier": {
    "doi": "10.1212/01.wnl.0000204235.81272.e2"
  },
  "journal": "Neurology",
  "publisher": "Ovid Technologies (Wolters Kluwer Health)",
  "title": "Randomized controlled phase II trial of glatiramer acetate in ALS"
}
